Title: Impairment of neurovascular coupling in Type 1 Diabetes Mellitus in rats is prevented by pancreatic islet transplantation and reversed by a semi-selective PKC inhibitor

Keywords: neurovascular coupling; diabetes mellitus type 1; potassium channels; PKC; pancreatic islet transplantation; GF109203X

Abstract: Streptozotocin (STZ)-induced chronic hyperglycemia has a detrimental effect on neurovascular coupling, linked to increased PKC-mediated phosphorylation and PKC isoform expression changes. Here, we sought to determine whether: 1) selective PKC-α/β/γ inhibitor, GF109203X, could reverse the effects of chronic hyperglycemia on cerebrovascular reactivity; 2) pancreatic islet transplantation could prevent the development of cerebrovascular impairment seen in a rat model of Type 1 Diabetes.

We studied the effect of GF109203X in diabetic (DM), non-diabetic (ND), and transplanted (TR) Lewis rats during either sciatic nerve stimulation (SNS) or the topical applications of the large-conductance Ca2+-operated K+ (BKCa) channel opener, NS1619, or the K+ inward rectifier (Kir) channel agonist, KCl. Pial arteriole diameter changes were monitored using a closed cranial window in vivo microscopy technique.

The pial arteriole dilatory response associated with SNS was decreased by ~45%, when comparing DM vs either ND or TR rats. Also, pial arteriolar dilations to topical KCl and NS1619 were largely suppressed in DM rats, but not in ND or TR animals. These responses were completely restored by the acute application of GF109203X to the brain surface. The PKC inhibitor had no effect on vascular responses in normoglycemic and TR animals.

In conclusion, DM-associated chronic impairment of neurovascular coupling may be readily reversed by a PKC-α/β/γ inhibitor or prevented via pancreatic islet transplantation. We believe that specific PKC isoforms (α/β/γ) are mechanistically linked to the neurovascular uncoupling seen with hyperglycemia.
Dear Editor,

We are pleased to propose for publication on Brain Research the present Manuscript titled: “Impairment of neurovascular coupling in Type 1 Diabetes Mellitus in rats is prevented by pancreatic islet transplantation and reversed by a semi-selective PKC inhibitor” by the following authors:

1. Francesco Vetri, MD PhD
   Title: Anesthesia resident
   Affiliation: Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA
   Email: vetri@uic.edu

2. Meirigeng Qi, MD PhD
   Title: Research assistant professor
   Affiliation: Division of Transplantation, Department of Surgery, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA
   (current affiliation: Department of Translational Research and Cellular Therapeutics, Diabetes and Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, CA, USA)
   Email: mqi@coh.org

3. Haoliang Xu, MD PhD
   Title: Research assistant professor
   Affiliation: Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA. Current affiliation: Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
   Email: hlxu@uic.edu

4. Jose Oberholzer, MD PhD
   Title: Director of Cell and Pancreas Transplantation
   Affiliation: Division of Transplantation, Department of Surgery, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA
   Email: jober@uic.edu

5. Chanannait Paisansathan, MD
   Title: Clinical professor
   Affiliation: Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA
Email: oon@uic.edu

Corresponding Author:
Francesco Vetri, MD PhD
Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, suite 3200W, Chicago, IL, 60612, USA
Phone: +1 7735329118
FAX: +1 3129964019
Email: vetri@uic.edu

In this paper, we show that the pial arteriole dilatory response associated with scatic nerve stimulation was decreased by ~45%, when comparing diabetic vs either non-diabetic or pancreatic islet-transplanted rats. Also, pial arteriolar dilations to topical KCl and the large conductance K+ channel opener, NS1619, were largely suppressed in diabetic rats, but not in non-diabetic or transplanted animals. These responses were completely restored by the acute application of the semiselective PKC inhibitor, GF109203X, to the brain surface. The PKC inhibitor had no effect on vascular responses in normoglycemic and TR animals. In brief, diabetes-associated chronic impairment of neurovascular coupling may be readily reversed by a PKC-α/β/γ inhibitor or prevented via pancreatic islet transplantation.

Thanks for your kind consideration,
Sincerely,
Francesco Vetri, MD PhD

Chicago, IL
08/31/2016
Highlights

- Neurovascular coupling was impaired in diabetic vs either non-diabetic (ND) or pancreatic islet transplanted-rats (TR).

- Pial arteriolar dilations to KCl and NS1619 were suppressed in diabetic rats, but not in ND or TR animals.

- These responses were completely restored by the acute application of a PKC inhibitor, GF109203X.

- The PKC inhibitor had no effect on vascular responses in normoglycemic and transplanted animals.

- Diabetes-associated chronic impairment of neurovascular coupling may be reversed by a PKC inhibitor.

- Diabetes-associated chronic impairment of neurovascular coupling may be prevented via pancreatic islet transplantation.
Joseph C LaManna PhD Case Western Reserve University, Cliveland, OH joseph.lamanna@case.edu

Robert Bryan PhD Baylor College of Medicine Houston, TX rbryan@bcm.edu

Charles Leffler PhD The University of Tennessee Health Science Center cleffler@uthsc.edu
Impairment of neurovascular coupling in Type 1 Diabetes Mellitus in rats is prevented by pancreatic islet transplantation and reversed by a semi-selective PKC inhibitor.

Francesco Vetri¹, MD PhD; Meirigeng Qi²,³, MD PhD; Haoliang Xu¹,⁴, MD PhD; Jose Oberholzer², MD PhD; Chanannait Paisansathan¹, MD

¹Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA

²Division of Transplantation, Department of Surgery, University of Illinois at Chicago, 1740 W Taylor St, Chicago, IL, 60612 USA

³Current affiliation: Department of Translational Research and Cellular Therapeutics, Diabetes and Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, CA, USA

⁴Current affiliation: Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.

Corresponding Author:

Francesco Vetri, MD PhD
Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, suite 3200W, Chicago, IL, 60612, USA
Phone: +1 7735329118
FAX: +1 3129964019
Email: vetri@uic.edu
Abstract

Streptozotocin (STZ)-induced chronic hyperglycemia has a detrimental effect on neurovascular coupling, linked to increased PKC-mediated phosphorylation and PKC isoform expression changes. Here, we sought to determine whether: 1) selective PKC-α/β/γ inhibitor, GF109203X, could reverse the effects of chronic hyperglycemia on cerebrovascular reactivity; 2) pancreatic islet transplantation could prevent the development of cerebrovascular impairment seen in a rat model of Type 1 Diabetes.

We studied the effect of GF109203X in diabetic (DM), non-diabetic (ND), and transplanted (TR) Lewis rats during either sciatic nerve stimulation (SNS) or the topical applications of the large-conductance Ca\(^{2+}\)-operated K\(^+\) (BK\(_{Ca}\)) channel opener, NS1619, or the K\(^+\) inward rectifier (Kir) channel agonist, KCl. Pial arteriole diameter changes were monitored using a closed cranial window in vivo microscopy technique.

The pial arteriole dilatory response associated with SNS was decreased by \(\sim 45\%\), when comparing DM vs either ND or TR rats. Also, pial arteriolar dilations to topical KCl and NS1619 were largely suppressed in DM rats, but not in ND or TR animals. These responses were completely restored by the acute application of GF109203X to the brain surface. The PKC inhibitor had no effect on vascular responses in normoglycemic and TR animals.

In conclusion, DM-associated chronic impairment of neurovascular coupling may be readily reversed by a PKC-α/β/γ inhibitor or prevented via pancreatic islet transplantation. We believe that specific PCK isoforms (α/β/γ) are mechanistically linked to the neurovascular uncoupling seen with hyperglycemia.
Key words
neurovascular coupling; diabetes mellitus type 1; potassium channels; PKC; pancreatic islet transplantation; GF109203X

1. Introduction

Neurovascular coupling (NVC) has been extensively studied over recent decades and many factors appear to participate in this process [4]. Among these, are diffusible paracrine factors released by astrocytes and neurons—e.g., ATP and K⁺, as well as cyclooxygenase and cytochrome P450 products. Indeed, such redundancy is thought to ensure an adequate O₂ and glucose supply to neurons when their energy demands increase over a wide array of conditions.

Type 1 Diabetes Mellitus is a widespread clinical condition [7], that is often associated with encephalopathy (for review see [25]). Indeed, cerebral complications of Type 1 Diabetes Mellitus include microangiopathy, retinopathy, and an increased risk of Alzheimer’s disease [29], stroke, mild cognitive impairment and dementia [2]. Strict glycemic control through intensive insulin therapy can slow, or even stop, the development of such complications [24].

---

1 aCSF, artificial cerebrospinal fluid
BKCa, large-conductance Ca²⁺-operated K⁺ channel
DM, diabetic
ND, non-diabetic
NVC, neurovascular coupling
Kir, K⁺ inward rectifier channel
PKC, protein kinase C
SEPs, somatosensory evoked potentials
STZ, streptozotocin
TR, transplanted rats
However, intensive insulin therapy is limited by an increased risk for severe hypoglycemic episodes [1]. Islet transplantation can provide glycemic control without exogenous insulin and without the risk of hypoglycemia [6,12,31]. Therefore, in recent years, pancreatic islet transplantation has emerged as a suitable therapeutic option in a selected patient population as a means of curing diabetes and preventing hyperglycemia-associated complications. In experimental animal models with chemically-induced chronic diabetes, evidence indicates a profound impairment in cerebral vasodilatory function [3,22]. We recently reported that neurovascular coupling is negatively affected by uncontrolled chronic hyperglycemia [40]. One possible mechanism responsible for this diabetes-related vascular impairment is chronic activation of protein kinase C (PKC) [28,40]. Findings from in vitro and in vivo models have indicated a vital role for inward rectifier and large conductance, Ca$^{2+}$-operated K$^+$ channels (Kir and BK$_{Ca}$, respectively) in neurovascular coupling [11,14,26]. According to these models, neuronal activation would lead to calcium increase in the astrocytic endfeet, where activation of BK$_{Ca}$ would result in K$^+$ release at the gliovascular interface and activation of Kir channels located on the vascular smooth muscle cells with subsequent hyperpolarization and vasodilation. Interestingly, the literature and our data suggest that Kir and BK$_{Ca}$ channels-mediated vasodilations are affected by diabetes [22] and sensitive to inhibition via PKC-mediated phosphorylation [10,20,32,40,43]. Importantly, our work showed that these vascular responses were completely restored by the acute topical application of a general PKC antagonist, calphostin C [40]. On the other hand, the suffusion of a PKC activator, phorbol 12,13-dibutyrate, in ND rats was able to reproduce the vascular reactivity impairments found in a rat model of Type 1 Diabetes Mellitus. Assay of PKC activity in brain samples from DM vs. ND rats revealed a significant gain in activity only in specimens rich in pial vascular plus superficial glia limitans.
(glio-pial) tissue, but not in bulk cortical gray matter [40]. A subsequent study examining the expression of PKC isoforms in both cerebral cortex and glio-pial tissue, has suggested the specific involvement of PKC-α and, possibly, PKC-βII in the diabetes-related impairment in neurovascular coupling [37]. In the present study, we used a well-established rat in vivo neurovascular coupling model, involving sciatic nerve stimulation-induced pial arteriolar dilation [38,42]. We addressed the core hypothesis that chronic hyperglycemia is accompanied by chronic activation of conventional PKC isoforms (especially α, βI, and βII) which, in turn, represses neurovascular coupling efficiency. Additional hypotheses arise from this central premise. First, one can prevent this PKC-linked vascular dysfunction via chronic glycemic normalization through pancreatic islet transplantation. Second, the neurovascular coupling efficiency impairment present in chronically diabetic rats relates to phosphorylation mediated by conventional PKC isoforms. Third, irrespective of the duration of the vascular dysfunction, it is readily reversible using acute PKC blockade via the semi-selective inhibitor of conventional PKC isoforms, GF109203X.

2. Results

Three sets of Lewis rats were used for this study: 1) euglycemic 4-6 month old non-diabetic controls (ND group, n=11); 2) streptozotocin (STZ)-treated diabetic rats (6 month old, 4 months post-STZ) (DM group, n=6); and 3) STZ-treated diabetic animals, subjected to pancreatic islet transplantation soon after the establishment of the diabetic model, studied 100 days after the transplant (TR group, n=7). Blood pressure, body weight, blood glucose, pH, pO2, and pCO2 values in the different groups are reported in Table1. As expected, body weight was decreased in
diabetic rats (DM), whereas blood glucose was increased compared to ND controls and transplanted animals. No other statistically significant differences were found between physiological parameters. The baseline diameters of the arterioles studied was $32.8 \pm 3.6 \mu m$ for ND, $31.5 \pm 2.4 \mu m$ for DM, and $34.5 \pm 2.7 \mu m$ for the TR group ($P>0.05$).

Three types of vasodilatory stimuli were used to test cerebrovascular function in the 3 different groups: sciatic nerve stimulation, NS1619 suffusion and $K^+$ suffusion. In a previous study, we showed that these dilatory responses were impaired in female Sprague-Dawley diabetic rats [40], but no data was available on the Lewis strain used for the present investigation. Therefore, our first endeavor was to compare dilatory responses in the two different rat strains in normo- and hyper-glycemic animals.

2.1. Pial arteriole response to sciatic nerve stimulation in normoglycemic, diabetic (hyperglycemic) and transplanted rats

A well established closed cranial window technique was used to monitor the reactivity of pial arterioles overlying the contralateral hindlimb area of the somatosensory cortex (~2 mm caudally to the bregma and 2-3 mm lateral to the sagittal suture). We compared pial arteriole dilations evoked by 20 seconds of sciatic nerve stimulation in ND control ($n=11$) and DM ($n=6$) rats. Consistent with previously reported data obtained in Sprague-Dawley rats [40], the average peak response in the Type 1 Diabetes Mellitus group was decreased by 45% (Fig. 1A; $P<0.05$; representative vascular response curves provided in Fig. 1C). We then evaluated SNS responses in animals subjected to pancreatic islet transplantation. In all animals ($n=7$) receiving syngeneic islets normoglycemia was restored immediately after transplantation and normal blood glucose levels were maintained up to for 4 months, when the rats were used for the neurovascular
reactivity experiments. On the day of the experiment, blood glucose levels in the ND and TR groups were not statistically different (Table 1). Noticeably, the normalization of the blood glucose prevented the depression of the SNS-induced dilation in the transplanted animals as compared to the untreated DM rats (Fig. 1A; \(P<0.05\)).

We then tested the PKC-\(\alpha/\beta/\gamma\) inhibitor, GF109203X, in both ND (n=4) and DM (n=6) rats to test the hypothesis that PKC-\(\alpha\) and/or \(\beta II\) might be responsible for the decreased cerebrovascular function detected in diabetic rats. Interestingly, GF109203X significantly increased the response to SNS in DM rats, producing a dilation not significantly different from controls (Fig.1B). This data is in accordance with the effect of a general PKC inhibitor, Calphostin C, used in a previous study [40]. On the other hand, the SNS response was not affected at all by GF109203X in ND animals (Fig.1B), while Calphostin C substantially decreased that response [40].

The somatosensory evoked potentials (SEPs) recorded during sciatic nerve stimulations, as reflected in the P1N1 amplitudes (Fig. 1D), did not show any significant differences when comparing ND (n = 4), ND+GF109203X (n = 4), DM (n = 6), DM+GF109203X (n = 6) and TR rats (n = 7) (\(P>0.05\)). Therefore, the changes in vascular responses to sciatic nerve stimulation in the different groups or treatments were not attributable to alterations in the neuronal activation induced by diabetes and/or drug application.

2.2. \(BK_{Ca}\) channel function in normoglycemic, diabetic (hyperglycemic), and transplanted rats

In the diabetic rats of the present study, vasodilations elicited by suffusion of the \(BK_{Ca}\) channel opener were depressed, similar to the findings reported in a recent paper from our laboratory [40] and others [22]. Thus, NS1619 (10 \(\mu\)M and 50 \(\mu\)M) induced a dose-dependent dilation of pial
arterioles in ND and TR animals (Fig. 2A). However, NS1619 failed to induce dilation in DM rats at 10 µM ($P<0.05$ vs ND and TR), but not at 50 µM ($P>0.05$). The pial arteriolar dilations to NS1619 were preserved in the TR group (Fig. 2A). The administration of GF109203X was able to reverse the effects of hyperglycemia on NS1619 (10 µM)-mediated dilations ($P<0.05$ at 10 and $P>0.05$ at 50 µM, respectively; Fig. 2B). In ND rats, GF109203X had no effect on the responses to NS1619 at both concentrations.

2.3. *Kir channel function in normoglycemic, hyperglycemic, and transplanted rats*

*Kir* channel-mediated dilation of pial arterioles is shown in Fig. 3. Suffusion with the *Kir* agonist, K⁺ (6 and 12 mM), dilated only ND and TR but not DM arterioles ($P<0.05$ for both concentrations compared to ND and TR groups). Pial arteriolar dilations to K⁺ were preserved in the TR group (Fig. 3A), demonstrating that glycemic control is able to prevent the loss of reactivity to this dilating agent.

On the other hand, similar to pial arteriolar responses to NS1619, the lost K⁺ responses in diabetic rats were restored to normal levels by the acute PKC inhibition via GF109203X ($P<0.05$ for both concentrations; Fig. 3B). These findings, therefore, suggest that the normalization of sciatic nerve stimulation responses in diabetic animals in the presence of GF109203X is the result of the restoration of the vascular dilations to NS1619 and K⁺. Moreover, similarly to NS1619, ND rats showed no significant changes in K⁺ responses in the presence of PKC inhibitor suffusion (Fig. 3B).
3. Discussion

There are two major findings in the present study: 1) the normalization of blood glucose, via pancreatic islet transplantation in STZ-treated rats, is able to prevent the deleterious effects on cerebrovascular regulation brought on by Type 1 Diabetes Mellitus; 2) the same improvement may be achieved, in chronically diabetic rats, by the topical administration of an inhibitor of conventional PKC isoforms, GF109203X.

Three types of vasodilatory stimuli were used to test cerebrovascular function in the 3 different groups: sciatic nerve stimulation, topically-applied NS1619, and topically-applied K⁺. Evidence from reports published to date support an important role for BK_{Ca} and Kir channels in the communication of a vasodilating signal between astrocytes and arterioles in the process of neurovascular coupling [11,14,26,40,41]. Additional findings point to a repression of BK_{Ca} and Kir channel function in diabetic, chronically hyperglycemic rats [22,40]. Present findings confirmed that the K⁺-channel dysfunction in diabetic rats plays a role in the repression of sciatic nerve stimulation-evoked pial arteriolar dilations. In a previous study, we showed that these dilatory responses were impaired in female Sprague-Dawley diabetic rats [40]. In the present study, we repeated those earlier experiments, but instead using male Lewis rats. We obtained similar results, with the exception that we observed a near-normal response in the diabetic male Lewis rats to the higher dose of NS1619 (50 µM). It has to be noted that NS1619 might have some off target effects, especially toward calcium channels[5]. However, this molecule has been used in a number of publications pertinent to cerebral circulation[15,26,40], making us confident that the results obtained in this paper are valid. We suspect that this difference may be related to the different strain and/or gender of the rats studied. Lewis rats were selected for the present study because they are an inbred strain commonly used in transplantation studies [34]. Indeed, a
syngeneic transplantation model was applied in order to eliminate the effect of immune rejection on the transplanted grafts [18]. By doing this, more stable outcome can be obtained to facilitate the further assessment of neurovascular coupling in the rats. In fact, the absence of an immune response toward the transplanted pancreatic islets, likely permitted maintenance of an optimal glycemic control at 4 months following the transplant (Table 1). Importantly, the cerebrovascular reactivities that we measured were never different when comparing transplanted and control animals. This data has strong relevance, since the prevention of chronic hyperglycemia appears to completely prevent the pathophysiologic changes associated with this rat model of uncontrolled type 1 diabetes. However, it yet has to be proven that such changes occur in humans either with unchecked diabetes or with widely fluctuating blood glucose levels. One future study might compare the efficacy of insulin parenteral treatment vs pancreatic islet transplantation in preventing this type of cerebral complication, inasmuch as the glycemic regulation associated with endogenously produced insulin might be superior to exogenous insulin therapeutic regimens.

There is some evidence in the literature of a detrimental effect of acute hyperglycemia on neurovascular coupling[9]. Dorner and coll. measured retinal vein diameter changes in healthy volunteers subjected to acute mild hyperglycemia and found that retinal vein dilatory responses to flickering light were depressed in the setting of hyperglycemia. Although, to our knowledge, in the neurovascular coupling literature there is no other mention of venular vasodilation in response to neural activation, this evidence suggests a possible detrimental influence of acute hyperglycemia on neurovascular coupling. Further studies will need to address this specific issue.
A key observation in the present study was that the losses in vasodilating function were due to the enhanced activation of one or more of the conventional PKC isoforms. This was based upon the finding that acute administration of a PKC blocker (GF109203X), with selectivity toward conventional PKC isoforms (i.e., α, βI, βII and γ), was accompanied by normalization of pial arteriolar reactivity to sciatic nerve stimulation, NS1619, and K⁺. Further evidence supporting a role for PKC-α (and perhaps PKC-βII) can be found in a recent paper from our laboratory [37]. Thus, we detected an enhanced protein expression of PKC-α and RACK-1 (which stabilizes the active form of PKC-βII) in the glio-pial tissue fraction. On the other hand, no changes in the PKC-γ isoform were noted.

PKC-α has been linked to the inhibition of ionic channels important for neurovascular coupling, such as inward rectifier K⁺ channels [27], and, less specifically, of large conductance-Ca²⁺ operated (BKCa) K⁺ channels [35]. PKC-α upregulation in diabetes has been documented in brain [30], kidney and heart [19]. Therefore, we speculate that the impairment of neurovascular coupling and cerebrovascular function, occurring in the rat model of Type 1 Diabetes Mellitus, may be mechanistically linked to an increase in PKC-α expression and activity in the pial vessels and/or the astrocytes in contact with them (glia limitans).

The role of PKC-βII in diabetes has been extensively studied, especially in the retina, where it mediates a host of deleterious vascular effects [8,17]. We and others [33] have shown that, PKC-βII protein abundance does not change in the diabetic cerebral cortex or in the glio-pial tissue. Yet, our data on the expression of RACK-1 points to a significant upregulation in the glio-pial tissue, but not in the cerebral cortex, of chronically diabetic rats. This finding could suggest an increased activity of PKC-βII in the diabetic condition, that might have been overlooked by other analyses based on the bulk cerebral cortex sampling. In addition, the role of PKC-βI in diabetes
and/or neurovascular coupling appears difficult to disentangle in the literature, probably due to the lack of specific blockers. In many instances, the regulation of PKC-\(\beta I\) and \(\beta II\) seems to follow a similar pattern and have similar pathophysiological implications \([8,13]\). Therefore, since the pharmacological intervention used in the present study does not allow one to discriminate between the effects of the single isoforms, we cannot, at this time, assign a specific role to PKC-\(\beta I\) in our model.

PKC-\(\gamma\) expression, on the other hand, is decreased in the diabetic glio-pial tissue \([37]\), making it less conceivable that the inhibition caused by GF109203X might exert its effect on cerebrovascular responses through an interaction with this isoform.

In a previous study \([40]\), we found that acute CalC topical exposure in normoglycemic rats was associated with a substantial repression of \(K^+\) and sciatic nerve stimulation-induced (but not NS1619-induced) dilations. In the present work, the use of GF109203X, which is selective for the classical PKC isoforms, lacked any effect on the cerebrovascular reactivities to sciatic nerve stimulation, NS1619 and \(K^+\). This finding suggests that the complex interactions between hyperglycemia and the different PKC isoforms expression/activity changes produce non-linear effects that are difficult to predict and would warrant further experimentations. Nevertheless, the information conveyed in this study is valuable, because it narrows down the wide array of PKC isoforms that might be involved in the pathophysiology of this diabetic complication and, more importantly, provides evidence for a complete and immediate reversal of a chronic impairment.

Another possible cause of decreased reactivity of the diabetic cerebral vessels, could be the endothelial dysfunction. However, we have demonstrated \([42]\) that, in our model, endothelium does not participate in the response to sciatic nerve stimulation. Another mechanism potentially implicated in the diminished neurovascular coupling response in the diabetic brain
could be an impaired neuronal function, as reflected in diminished sciatic nerve stimulation-evoked neuronal responses. This possibility, was ruled out not only by the absence of significant differences in sciatic nerve stimulation-evoked potential amplitudes when comparing diabetic and non-diabetic rats, but also when comparing the electrical responses in the absence and in the presence of GF109203X.

In conclusion, the dysregulation of cerebral perfusion accompanying chronic hyperglycemia, in rat models of type 1 diabetes mellitus, is well-documented. The above pathophysiologic process has been shown to include loss of BK$_{Ca}$ and Kir channel-mediated vasodilating functions as well as a significant decrease in the pial arteriolar dilations evoked by somatosensory activation, via sciatic nerve stimulation, in streptozotocin-treated diabetic rats. Present results also suggested that the restoration and maintenance of normoglycemia, via the endogenous production of insulin from transplanted pancreatic islets, are able to prevent the compromise of neurovascular coupling observed in diabetic animals. Moreover, the acute topical administration of an inhibitor of the classical PKC isoforms, GF109203X, was capable of reversing the diabetic cerebrovascular impairments. Both of these neuroprotective mechanisms might have significant clinical implications.

4. Experimental procedures

4.1 Surgical procedures. Adult Lewis male rats (4-6 month old, n=24) were used for cranial window experiments. Experimental procedures were approved by the Animal Care and Use Committee of the University of Illinois at Chicago. As detailed in previously published reports [26,40,42], on the day of the experiment, rats were anesthetized with isoflurane, and mechanically ventilated after orotracheal intubation. The femoral artery and vein on the side not used for the nerve stimulation were cannulated for blood sampling, arterial pressure monitoring,
and drug infusions. Rectal temperature was servo-controlled at 37°C. A 10 mm diameter craniotomy was performed over the skull midline. After carefully removing the dura, a glass window outfitted with three ports (artificial cerebrospinal fluid (aCSF) inflow, aCSF outflow, and ICP monitoring) was mounted for pial vessel observation. The space under the cranial window was suffused with aCSF. One hour prior to drug or sciatic nerve stimulation testing, isoflurane was replaced by fentanyl, and anesthesia was maintained with 25 μg/kg/h fentanyl / 70 \% N_2O / 30 \% O_2. After negative movement response to tail and paw pinch, paralysis was then induced with d-tubocurarine. Temperature, invasive mean arterial blood pressure, and intracranial pressure were continuously monitored and maintained within normal limits. Arterial blood samples were taken at 60-min intervals and analyzed using a blood gas/pH analyzer (Gem3000, Instrumentation Laboratories, Lexington, MA). PaO_2, PaCO_2, and pH were maintained within physiologic ranges throughout the study.

4.2. Diabetes model and transplantation procedures. Diabetes was induced with a single i.p. streptozotocin (STZ, Sigma, St. Louis, MO) injection (80 mg/kg, freshly dissolved in citrate buffer, pH 4.5) to 2 month old rats (n=13), around 16-18 weeks prior to the experiment. Animals were considered to be diabetic when blood glucose exceeded 350 mg/dL for two consecutive days after STZ. Blood glucose was measured twice a week (Contour glucometer, Bayer, Mishawaka, IN) for the entire period prior to study. Animals in the DM group (n=6) received no insulin.

Syngeneic pancreatic islet transplantation was conducted in the recipient diabetic rats (n=7) using the method described previously [16]. Briefly, donor islets were isolated by conventional collagenase method and cultured at 37°C/5% CO_2. On the day of transplantation, 1,000 islets were pooled and prepared for each recipient rat. Under isoflurane anesthesia, a midline incision
was made and portal vein was exposed. The islets were injected into the portal vein in 0.3 ml of the same medium through a 25 G needle. After withdrawal of the needle, the injection site was compressed for 2 minutes to minimize blood loss. The incision was closed subsequently and animal was followed for full recovery. Postoperative pain was controlled with scheduled buprenorhine sc injections.

4.3. Experimental protocol. In the typical neurovascular coupling experiment, 1 hour after the anesthesia switch from isoflurane to fentanyl, and regular aCSF suffusion (equilibration period), the rats were subjected to one or two sciatic nerve stimulation episodes followed by NS1619 (10 and 50 µM) or K⁺ (KCl 6 and 12 mM) suffusions under the cranial window for 5 min at each concentration. In the DM and ND groups, after a recovery period of at least 5 min, we initiated a suffusion of GF109203X (also known as Bisindolylmaleimide I or Gö 6850). GF109203X, at 20 nM, tends to favor the inhibition of PKC-α (IC₅₀ of 8 nM). However, such concentration is thought to inhibit also PKC-βI, -βII and -γ (IC₅₀ of 18, 20, and 21 nM, respectively), but not other PKC isoforms, e.g. δ, ε and ζ (IC₅₀ of 210, 132 and 5800 nM, respectively) [21,36]. Therefore, all the conventional PKC isoforms might be similarly affected by GF109203X. Pial arteriolar diameter changes, relative to baseline, after 40 min suffusion of GF109203X (20 nM) under the cranial window were modest and not significantly different when comparing non-diabetic and diabetic rats (-2 ± 3% and -3 ± 6 %, respectively; P > 0.05). Forty minutes later, a second sciatic nerve stimulation was imposed, followed by re-evaluation of NS1619 and K⁺-induced dilations.

2.4 Video imaging and data analysis. Intravital video microscopy was used to study pial arteriole diameter changes in response to drugs and/or sciatic nerve stimulation [40]. Images were acquired through a CCD camera (Photometrics, Tucson, AZ) mounted on an upright
stereomicroscope (Nikon, Melville, NY). We studied arterioles overlying the hindlimb somatosensory cortex [23]. Starting at 20 s prior to sciatic nerve stimulation and continuing for 60 s post-sciatic nerve stimulation, pial arterioles were monitored and the recordings saved for subsequent analysis. Arteriolar diameter changes were measured off line using Metamorph software (MDS Analytical Technologies, Sunnyvale, CA). The diameter values of 3 different pial arterioles were averaged for each time point. The peak dilation induced by sciatic nerve stimulation was calculated as the percent change relative to the baseline, where baseline was taken as the average diameter value measured over 20 s immediately preceding sciatic nerve stimulation. The dilation induced by NS1619 or K+ was measured after 5 min of perfusion and compared to the baseline diameter.

4.5. Sciatic nerve stimulation and electrophysiologic recordings. The experiments were conducted according to previously published techniques. Briefly, the sciatic nerve on one side was surgically exposed and sectioned. A ring electrode was carefully secured to the nerve ending and connected to an isolated stimulator unit (Stimulator HC, ML155, AD Instruments, Sidney, Australia) controlled via Labchart 7 software (AD Instruments) [39,40]. Electrophysiologic recordings of the somatosensory evoked potentials (SEPs) were obtained through stainless steel screws placed on the border of the cranial window. The signal was amplified, bandpass filtered (0.1-1kHz) and digitized by a PowerLab acquisition board (AD Instruments). Peak-to-peak N1P1 and N2P2 amplitudes were measured and compared before and after administration of GF109203X (and in ND vs DM, and ND vs TR) to evaluate possible effects on SEPs. Values were obtained by averaging 2-4 trains of stimuli per each condition. No significant differences were detected (Fig.1, D).
4.6 Drugs. NS1619 and streptozotocin were obtained from Sigma-Aldrich (St. Louis, MO). GF109203X was purchased from Tocris Bioscience (Bristol, UK).

4.7. Statistical analysis. Statistical comparisons between groups were performed using one-way ANOVA with Tukey post-hoc correction, while the effect of treatments within the same experiment was evaluated via repeated measure one-way ANOVA. Data are expressed as Mean ± sd. Statistical significance was set at $P = 0.05$; $n$ refers to the number of experimental animals.

Acknowledgements:
This work was supported by NIH grant 5 RO1 NS0672379-04 to Dale.A. Pelligrino, JDRF postdoctoral fellowship 3-2008-462 to F.V., NIH (ICR Grant 1 U42 RR023245-01) and JDRF grants (#5-2006-398) to J.O.
We would like to thank Dale A. Pelligrino for his guidance and input on this research and dedicate this paper to his memory
References


Table Legend

Table 1  Vital parameters in normoglycemic control (ND), type 1 diabetic (DM) and transplanted (TR) rats. Mean arterial blood pressure, blood glucose, body weight, arterial blood pH, partial pressure of oxygen (pO₂), and partial pressure of carbon dioxide (pCO₂) were recorded on the day of experiment. (*, P < 0.05 vs ND and TR)

Figure Legends

Fig. 1  Neurovascular coupling impairment in 4 month diabetic (T1DM) rats. (A) Sciatic nerve stimulation (SNS)-evoked pial arteriolar responses in type 1 diabetes mellitus rats (DM, n = 6) show a ~45% decrease in the peak diameter change compared to non-diabetic controls (ND, n = 11) or animals subjected to pancreatic islet transplantation (TR, n = 7) (*, P < 0.05). (B) SNS-evoked responses before and after topical suffusion of the classical PKC isoform inhibitor, GF109203X, in ND (n = 4) and DM (n = 6) rats (*, P < 0.05 vs ND and ND + GF109203X; #, P < 0.05 vs DM + GF109203X). (C) Representative time courses of SNS-evoked pial arteriolar diameter changes in non-diabetic control (open circles) and T1DM (closed circles) rats. SNS duration is indicated by the black bar. (D) Summary of the somatosensory evoked potentials (SEPs) P1N1 peak-to-peak amplitudes recorded from ND, ND treated with GF109203X, DM, DM treated with GF109203X, and TR rats. No significant differences were observed.

Fig. 2  (A) Pial arteriolar diameter changes (expressed as a percentage of the baseline diameter) elicited by suffusion of the specific activator of BKCa channels, NS1619(10 µM and 50 µM), in control (ND, n = 11), type 1 diabetes mellitus (DM, n = 6), and transplanted (TR, n = 7) rats (*, P < 0.05). (B) Pial arteriolar responses to NS1619 before and after topical suffusion of the
classical PKC isoform inhibitor, GF109203X, in ND (n = 4) and DM (n = 6) rats (*, P < 0.05 vs ND and ND + GF109203X; #, P < 0.05 vs DM + GF109203X).

Fig. 3  (A) Pial arteriolar diameter changes (expressed as a percentage of the baseline diameter) elicited by suffusion of the specific activator of Kir channels, K⁺ (6 and 12 mM), in control (ND, n = 11), type 1 diabetes mellitus (DM, n = 6), and transplanted (TR, n = 7) rats (*, P < 0.05 for both concentrations). (B) Pial arteriolar responses to K⁺ before and after topical suffusion of the classical PKC isoform inhibitor, GF109203X, in ND (n = 4) and DM (n = 6) rats (*, P < 0.05 vs ND and ND + GF109203X; #, P < 0.05 vs DM + GF109203X for both concentrations).
Figure 2
Click here to download Figure: Figure 2.pdf
Figure 3

Click here to download Figure: Figure 3.pdf
Table 1. Vital parameters in normoglycemic control (ND), diabetic (DM) and transplanted (TR) rats.

<table>
<thead>
<tr>
<th>Vital parameter</th>
<th>ND</th>
<th>DM</th>
<th>TR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean arterial blood pressure (mmHg)</td>
<td>116±9</td>
<td>106±9</td>
<td>115±6</td>
</tr>
<tr>
<td>Blood glucose (mg/dl)</td>
<td>134±10</td>
<td>559±27*</td>
<td>171±35</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>430±18</td>
<td>228±19*</td>
<td>464±23</td>
</tr>
<tr>
<td>Blood pH</td>
<td>7.42±0.02</td>
<td>7.39±0.02</td>
<td>7.41±0.02</td>
</tr>
<tr>
<td>Blood pO₂ (mmHg)</td>
<td>123±20</td>
<td>127±15</td>
<td>122±15</td>
</tr>
<tr>
<td>Blood pCO₂ (mmHg)</td>
<td>42±1</td>
<td>39±1</td>
<td>40±1</td>
</tr>
</tbody>
</table>